Your Cart is Empty

Back To Shop

Nandrolone Decanoate 300mg 10ml – Watson Steroid in USA



Every 1ml. Contains:

Nandrolone decanoate 300 mg.


Watson Decanoate Nandrolone is an injectable anabolic preparation. The pharmacologically active substance is Nandrolone.

The Decanoate ester provides the preparation with a duration of action of approximately 3 weeks after injection. Nandrolone is chemically related to the male hormone.

Nandrolone Decanoate 300mg 10ml – Watson Steroid in USA


Compared to Testosterone, it has a marked anabolic activity and a reduced androgenic activity.

This has been demonstrated in animal bioassays and clarified by receptor binding studies. The low androgenicity of nandrolone is confirmed by clinical use.

Nandrolone Decanoate has been shown to positively influence calcium metabolism and increase bone mass in osteoporosis. In women with disseminated carcinoma of the breast, it has been reported to produce objective regressions over many months. In addition, Nandrolone has a nitrogen sparing action.

This effect on protein metabolism was confirmed in metabolic studies and is used therapeutically in states where there is a protein deficiency, such as during chronic debilitating diseases and after major surgery and severe trauma.

In these states, Nandrolone serves as a support adjuvant in specific treatments and dietary measures, as well as parenteral nutrition.

At recommended doses, androgenic effects (eg virilization) are relatively rare. Nandrolone lacks the C 17 alpha-alkyl group which is associated with the occurrence of hepatic dysfunction and cholestasis.

Nandrolone Decanoate is slowly released from the injection site into the blood with a half-life of 6 days. In the blood, the ester is rapidly hydrolyzed to nandrolone with a half-life of one or less.

The half life for the combined process of nandrolone decanoate hydrolysis and Nandrolone distribution and elimination is 4.3 hours.

Nandrolone is metabolized by the liver.

The substances 19-norandrosterone, 19-norethocolanolone and 19-norepiandrosterone have been identified as metabolites in urine.

It is not known whether these metabolites have any pharmacological action.

Therapeutic indications:

Stimulant of protein anabolism.


For the palliative treatment of selected cases of disseminated mammary carcinoma in women.

As an adjunct in specific therapeutics and dietary measures in pathological states characterized by a negative nitrogen balance.

Note: Adequate amounts of vitamins, minerals, and protein need to be administered in a high calorie diet for optimal therapeutic effect.

Secondary and adverse reactions:

High doses, prolonged treatment and/or too frequent administration can cause:

Virilization manifested in sensitive women as hoarseness, acne, hirsutism, and increased libido; in boys before puberty, as increased frequency of erections and phallic enlargement, and in girls as increased pubic hair and clitoral hypertrophy. Hoarseness can be the first symptom of a vocal change that can lead to sometimes irreversible deepening of the voice.


Inhibition of spermatogenesis.

Premature epiphyseal closure.

Fluid retention.


Pregnancy. Prostatic carcinoma or known or suspected mammary carcinoma in men. This medication is contraindicated during pregnancy due to the possibility of masculinization of the fetus. There are insufficient data on the use of this medicine during lactation to establish potential harm to the baby or a possible influence on milk production.

Precautions and Warnings (in relation to effects of carcinogenesis, mutagenesis, teratrogenesis and on fertility).

If signs of virilization develop, discontinuation of treatment should be considered, preferably after consultation with the patient.

Monitoring of patients with any of the following conditions is recommended.

Latent or overt heart failure, renal dysfunction, hypertension or migraine (or history of these conditions) as anabolic steroids may include fluid retention.

Incomplete natural growth since high dose anabolic steroids can accelerate epiphyseal closure.

Metastases in the skeleton or breast carcinoma. In these patients, hypercalcaemia can develop spontaneously in both cases and as a result of anabolic steroid therapy. The latter may be indicative of a positive tumor response to hormonal treatment.

However, hypercalcemia must first be treated appropriately and then hormone therapy resumed once normal calcium levels have been restored.

Liver failure.

The misuse of anabolic steroids to enhance sports ability carries with it serious health risks and should be discouraged.

Drug and other interactions:

Anabolic steroids can improve glucose tolerance and reduce the need for insulin or other antidiabetic drugs in diabetic patients.


It must be administered by deep intramuscular injection.

Osteoporosis: 50 mg. Every 3 weeks.

Palliative treatment in selected cases with disseminated mammary carcinoma in women: 50 mg. Every 2-3 weeks.

As an adjunct in specific therapeutics and dietary measures in pathological states characterized by a negative nitrogen balance: 20-50mg. Every 3 weeks.

Overdose or accidental ingestion:

The toxicity of Nandrolone Decanoate in animals is very low.

There are no reports of acute overdosage with Nandrolone in humans.

Buy anabolic steroids online in USA.


Your Cart is Empty

Back To Shop